MX346453B - Medicamento profilactico o terapeutico para el estreñimiento. - Google Patents

Medicamento profilactico o terapeutico para el estreñimiento.

Info

Publication number
MX346453B
MX346453B MX2015010029A MX2015010029A MX346453B MX 346453 B MX346453 B MX 346453B MX 2015010029 A MX2015010029 A MX 2015010029A MX 2015010029 A MX2015010029 A MX 2015010029A MX 346453 B MX346453 B MX 346453B
Authority
MX
Mexico
Prior art keywords
therapeutic drug
constipation
prophylactic
drug
useful
Prior art date
Application number
MX2015010029A
Other languages
English (en)
Other versions
MX2015010029A (es
Inventor
Daisuke Yamamoto
Fusayo Io
Koji Yamamoto
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of MX2015010029A publication Critical patent/MX2015010029A/es
Publication of MX346453B publication Critical patent/MX346453B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proveen nuevos fármacos útiles en la prevención o tratamiento del estreñimiento, en los que están contenidos como ingredientes activos compuestos inhibidores de SGLT1, en particular un compuesto de 4-isopropilfenil glucitol representado por la siguiente fórmula (I), o sales farmacéuticamente aceptables de los mismos. (ver Fórmula).
MX2015010029A 2013-02-04 2014-02-03 Medicamento profilactico o terapeutico para el estreñimiento. MX346453B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013019754 2013-02-04
PCT/JP2014/052465 WO2014119787A1 (ja) 2013-02-04 2014-02-03 便秘症の予防又は治療薬

Publications (2)

Publication Number Publication Date
MX2015010029A MX2015010029A (es) 2015-10-30
MX346453B true MX346453B (es) 2017-03-17

Family

ID=51262485

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010029A MX346453B (es) 2013-02-04 2014-02-03 Medicamento profilactico o terapeutico para el estreñimiento.

Country Status (17)

Country Link
US (1) US10022389B2 (es)
EP (1) EP2952206B1 (es)
JP (1) JP5807767B2 (es)
KR (1) KR102078433B1 (es)
CN (1) CN104955481B (es)
AU (1) AU2014213251B2 (es)
BR (1) BR112015017541A2 (es)
CA (1) CA2899834C (es)
ES (1) ES2694110T3 (es)
IL (1) IL240192A (es)
MX (1) MX346453B (es)
MY (1) MY176162A (es)
PH (1) PH12015501696A1 (es)
RU (1) RU2648467C2 (es)
SG (2) SG10201700267PA (es)
TW (1) TWI659739B (es)
WO (1) WO2014119787A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019142774A (ja) * 2016-06-20 2019-08-29 大正製薬株式会社 腸内環境改善剤

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2830424C3 (de) 1978-07-11 1982-04-15 Bayer Ag, 5090 Leverkusen alpha -Glucosidase-Inhibitoren
US5651988A (en) 1995-08-18 1997-07-29 Xyrofin Oy Combination osmotic and bulk forming laxatives
BRPI0313290B1 (pt) 2002-08-08 2016-12-06 Kissei Pharmaceutical derivados de pirazol, promedicamento, composição farmacêutica, agentes terapêuticos e uso medicinal
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
AU2003262262A1 (en) 2002-08-27 2004-03-19 Kissei Pharmaceutical Co., Ltd. Pyrazole derivatives, medicinal composition containing the same, and medicinal use thereof
EP1568380A4 (en) 2002-12-04 2009-10-21 Kissei Pharmaceutical PREVENTION OR TREATMENT OF DISEASES DUE TO HYPERGLYCEMIA
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
AR061026A1 (es) 2006-05-19 2008-07-30 Taisho Pharmaceutical Co Ltd Compuesto glicitol c-fenilo y preparacion farmaceutica
CA2655937A1 (en) 2006-06-29 2008-01-03 Taisho Pharmaceutical Co., Ltd. C-phenyl 1-thioglucitol compound
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
AU2007332476A1 (en) 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. 1-phenyl 1-thio-D-glucitol derivative
GB2447067A (en) 2007-02-20 2008-09-03 Branko R Babic Alteration of osmotic gradients by polyhydroxy compounds
CA2709530C (en) 2007-12-27 2016-02-23 Kissei Pharmaceutical Co., Ltd. Monosebacate of pyrazole derivative
US8354382B2 (en) 2008-04-16 2013-01-15 Kissei Pharmaceutical Co., Ltd. Hemifumarate of a pyrazole derivative
MY155658A (en) 2009-02-23 2015-11-13 Taisho Pharmaceutical Co Ltd A-isopropylphenyl glucitol compounds as sglti inhibitors
JP2013224263A (ja) 2010-08-19 2013-10-31 Taisho Pharmaceutical Co Ltd ４−イソプロピルフェニルグルシトール化合物
ES2546253T3 (es) 2010-08-20 2015-09-22 Taisho Pharmaceutical Co., Ltd. Compuesto 4-isopropil-6-metoxifenilglucitol
CA2807755A1 (en) 2010-08-20 2012-02-23 Taisho Pharmaceutical Co., Ltd. Crystal form of 4-isopropylphenyl glucitol compound and process for production thereof
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
PL2848254T3 (pl) 2012-05-07 2017-03-31 Kissei Pharmaceutical Co., Ltd. Pochodne pirazolu i ich zastosowanie w celach medycznych
UA117574C2 (uk) 2012-11-20 2018-08-27 Лексікон Фармасьютікалз, Інк. Інгібітори котранспортера натрій-глюкози 1

Also Published As

Publication number Publication date
PH12015501696B1 (en) 2015-10-12
BR112015017541A2 (pt) 2017-07-11
EP2952206B1 (en) 2018-10-24
TWI659739B (zh) 2019-05-21
CA2899834C (en) 2020-09-01
IL240192A0 (en) 2015-09-24
WO2014119787A1 (ja) 2014-08-07
TW201517903A (zh) 2015-05-16
IL240192A (en) 2017-03-30
MY176162A (en) 2020-07-24
SG10201700267PA (en) 2017-02-27
KR20150112949A (ko) 2015-10-07
EP2952206A1 (en) 2015-12-09
US20150374735A1 (en) 2015-12-31
RU2648467C2 (ru) 2018-03-26
CA2899834A1 (en) 2014-08-07
PH12015501696A1 (en) 2015-10-12
JPWO2014119787A1 (ja) 2017-01-26
ES2694110T3 (es) 2018-12-18
AU2014213251A1 (en) 2015-08-27
CN104955481A (zh) 2015-09-30
CN104955481B (zh) 2017-10-24
EP2952206A4 (en) 2016-06-15
KR102078433B1 (ko) 2020-02-17
MX2015010029A (es) 2015-10-30
JP5807767B2 (ja) 2015-11-10
AU2014213251B2 (en) 2017-07-20
US10022389B2 (en) 2018-07-17
RU2015137671A (ru) 2017-03-10
SG11201506047PA (en) 2015-09-29
HK1211479A1 (en) 2016-05-27

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
MX2015003594A (es) Agente terapeutico o profilactico para sindrome de lisis tumoral.
PH12018500904A1 (en) Peptide macrocycles against acinetobacter baumannii
MX363127B (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
MX2015008975A (es) Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn).
PH12016500756A1 (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
PH12015501996A1 (en) Heterocyclic compounds and uses thereof
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
PH12015501363B1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
MX364400B (es) Compuestos de tetraciclina.
PH12016502246B1 (en) Carboxamide derivatives
MX2016014946A (es) Derivados de carboxamida.
PH12015501696A1 (en) Prophylactic or therapeutic drug for constipation
MX2016005160A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MX358470B (es) Administracion de eritoran o sales farmaceuticamente aceptables del mismo para tratar infecciones para ortomixovirus.
MX2016005539A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
NZ719215A (en) Pharmaceutical compositions comprising antibacterial agents
MX2016009932A (es) Agente terapeutico o profilactico para esclerosis multiple.
GEAP201914604A (en) Therapeutic agent for frontal lobe dysfunction
PH12019501027A1 (en) Therapeutic drug or prophylactic drug for diabetic nephropathy
PH12016502247A1 (en) Carboxamide derivatives

Legal Events

Date Code Title Description
FG Grant or registration